echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JAMA Oncol: Vistusertib in combination with anastrozole for hormone receptor-positive endometrial cancer

    JAMA Oncol: Vistusertib in combination with anastrozole for hormone receptor-positive endometrial cancer

    • Last Update: 2022-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Endometrial cancer is often hormone-dependent and can be treated with aromatase inhibito.

    Dysregulation of the PI3K-AKT-mTOR pathway has been observed to drive hormone resistance in endometrial cancer, suggesting that mTOR inhibitors can be used in combination with endocrine thera.

    This study (VICTORIA) was designed to evaluate the safety and efficacy of the mTOR inhibitor Vistusertib in combination with anastrozole in the treatment of hormone receptor-positive recurrent or metastatic endometrial canc.

    This is a multicenter, open-label, randomized clinical trial that enrolled 75 patients with hormone receptor-positive recurrent/metastatic endometrial cancer between April 2016 and October 2019 , randomized 2: 1 Divided into two groups, received Vistusertib (125mg*2 times/day, 2 days/week) and anastrozole (1mg/day, orally) or anastrozole alo.

    The primary endpoints were serious adverse events and progression-free rate (8wk-PFR) at weekSecondary endpoints were objective response rate, duration of response, progression-free survival (PFS), overall survival and incidence of adverse even.

    75 The primary endpoints were serious adverse events and progression-free rate (8wk-PFR) at week


    Progression-free survival in both groups


    Progression-free survival
    in both groups Progression-free survival in both groups

    Of the 75 patients enrolled, 73 (median age 65 years) received study treatment: 49 in the combination group and 24 in the anastrozole gro.

    Week 8 progression-free rates in the combination and anastrozole groups were 63% and 31%, respectively


    No significant serious adverse events were observ.


    The 8-week progression-free rates in the combination and anastrozole groups were 63% and 31%, respective.



    In conclusion, the results of this study show that the addition of anastrozole to the mTOR inhibitor Vistusertib can improve the progression-free rate, remission rate, prolong progression-free survival , and reduce adverse reactions in patients with hormone receptor-positive recurrent/metastatic endometrial canc.


    Anastrozole plus mTOR inhibitor Vistusertib can improve the progression-free rate and remission rate in patients with hormone receptor-positive recurrent/metastatic endometrial cancer, and prolong progression-free survival Anastrozole plus mTOR inhibitor Vistusertib can Improve progression-free and remission rates and prolong progression-free survival in patients with hormone receptor-positive recurrent/metastatic endometrial cancer

     

    Original source:

    Original source:

    Heudel P, Frenel J, Dalban C, et .


    Heudel P, Frenel J, Dalban C, et .
    Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Tri.
    JAMA Onc.
    Published online May 12, 202 doi:11001/jamaonc.
    202104 JAMA Comments Here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.